摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-溴-2-噻吩磺酰氯 | 185329-76-4

中文名称
4-溴-2-噻吩磺酰氯
中文别名
——
英文名称
4-bromothiophene-2-sulfonyl chloride
英文别名
——
4-溴-2-噻吩磺酰氯化学式
CAS
185329-76-4
化学式
C4H2BrClO2S2
mdl
MFCD01763894
分子量
261.548
InChiKey
IMVRMHNCGCAEES-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    322.2±27.0 °C(Predicted)
  • 密度:
    1.985±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.6
  • 重原子数:
    10
  • 可旋转键数:
    1
  • 环数:
    1.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    70.8
  • 氢给体数:
    0
  • 氢受体数:
    3

安全信息

  • 危险品标志:
    C
  • 安全说明:
    S26,S36/37/39,S45
  • 危险类别码:
    R34

SDS

SDS:1e905ad60d2cdb7b52dd39f54b1ff8f6
查看
Name: 4-Bromo-2-thiophenesulfonyl chloride 97% Material Safety Data Sheet
Synonym:
CAS: 185329-76-4
Section 1 - Chemical Product MSDS Name:4-Bromo-2-thiophenesulfonyl chloride 97% Material Safety Data Sheet
Synonym:

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS
CAS# Chemical Name content EINECS#
185329-76-4 4-Bromo-2-thiophenesulfonyl chloride 97% unlisted
Hazard Symbols: C
Risk Phrases: 34

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Causes burns.Moisture sensitive.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Causes skin burns.
Ingestion:
Causes gastrointestinal tract burns.
Inhalation:
Causes chemical burns to the respiratory tract.
Chronic:
Not available.

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area. Store under nitrogen.

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 185329-76-4: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 110.4 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C4H2BrClO2S2
Molecular Weight: 261.55

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials, exposure to moist air or water.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, carbon monoxide, oxides of sulfur, carbon dioxide, hydrogen bromide, bromine.
Hazardous Polymerization: Has not been reported

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 185329-76-4 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
4-Bromo-2-thiophenesulfonyl chloride - Not listed by ACGIH, IARC, or NTP.

Section 12 - ECOLOGICAL INFORMATION


Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.*
Hazard Class: 8
UN Number: 3261
Packing Group: III
IMO
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE SOLID, ACIDIC, ORGANIC, N.O.S.
Hazard Class: 8
UN Number: 3261
Packing group: III

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 185329-76-4: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 185329-76-4 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 185329-76-4 is not listed on the TSCA inventory.
It is for research and development use only.


SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

  • 作为反应物:
    描述:
    4-溴-2-噻吩磺酰氯氯化铵 作用下, 以 四氢呋喃 为溶剂, 生成 4-Benzylsulfanylthiophene-2-sulfonamide
    参考文献:
    名称:
    Heterocycle RMB39 Modulators
    摘要:
    Provided herein are compounds that modulate RMB39 and methods of using the compounds in RMB39-associated disorders, such as cancer (e.g., renal cell carcinoma).
    公开号:
    US20240092770A1
  • 作为产物:
    描述:
    2,4-二溴噻吩异丙基氯化镁二氧化硫N-氯代丁二酰亚胺 作用下, 以 四氢呋喃 为溶剂, 反应 2.5h, 生成 4-溴-2-噻吩磺酰氯
    参考文献:
    名称:
    [EN] 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE
    [FR] COMPOSÉS DE 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDÈNE)ACÉTAMIDE ET LEUR UTILISATION THÉRAPEUTIQUE
    摘要:
    本发明一般涉及治疗化合物领域。更具体地,本发明涉及某些2-氨基-N-(氨基氧代芳基-λ6-砜基)乙酰胺化合物(以下简称为ANASIA化合物),该化合物在一些情况下抑制(例如,选择性抑制)细菌氨酰-tRNA合成酶(aaRS)(例如,细菌亮氨酰-tRNA合成酶,LeuRS)。本发明还涉及包含这种化合物的药物组合物,以及在体内外使用这种化合物和组合物来抑制(例如,选择性抑制)细菌氨酰-tRNA合成酶;治疗通过抑制(例如,选择性抑制)细菌氨酰-tRNA合成酶而得到改善的疾病;治疗细菌感染等。
    公开号:
    WO2021123237A1
点击查看最新优质反应信息

文献信息

  • HEPATITIS B ANTIVIRAL AGENTS
    申请人:ENANTA PHARMACEUTICALS, INC.
    公开号:US20160289212A1
    公开(公告)日:2016-10-06
    The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: X-A-Y-Z-L-R 1 (I) which inhibit the protein(s) encoded by hepatitis B virus (HBV) or interfere with the function of the HBV life cycle of the hepatitis B virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HBV infection. The invention also relates to methods of treating an HBV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    本发明公开了化合物的结构式(I),或其药学上可接受的盐、酯或前药: X-A-Y-Z-L-R 1 (I) 这些化合物抑制由乙型肝炎病毒(HBV)编码的蛋白质或干扰乙型肝炎病毒的生命周期功能,并且还可用作抗病毒剂。本发明还涉及包括上述化合物的药物组合物,用于治疗患有HBV感染的受试者。该发明还涉及通过给予包含本发明化合物的药物组合物来治疗受试者的HBV感染的方法。
  • N-aryl thienyl-, furyl-, and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
    申请人:Texas Biotechnology Corp.
    公开号:US06342610B2
    公开(公告)日:2002-01-29
    Thienyl-, furyl- and pyrrolyl-sulfonamides and methods for modulating or altering the activity of the endothelin family of peptides are provided. In particular, N-(isoxazolyl)thienylsulfonamides, N-(isoxazolyl)furylsulfonamides and N-(isoxazolyl)pyrrolylsulfonamides and methods using these sulfonamides for inhibiting the binding of an endothelin peptide to an endothelin receptor by contacting the receptor with the sulfonamide are provided. Methods for treating endothelin-mediated disorders by administering effective amounts of one or more of these sulfonamides or prodrugs thereof that inhibit or increase the activity of endothelin are also provided.
    提供了噻吩基、呋喃基和吡咯基磺酰胺以及用于调节或改变内皮素肽家族活性的方法。特别是,提供了N-(异恶唑基)噻吩磺酰胺、N-(异恶唑基)呋喃磺酰胺和N-(异恶唑基)吡咯磺酰胺以及使用这些磺酰胺通过将受体与磺酰胺接触来抑制内皮素肽与内皮素受体结合的方法。还提供了通过施用有效量的一个或多个这些磺酰胺或其前药来治疗内皮素介导的疾病的方法,这些磺酰胺或其前药抑制或增加内皮素的活性。
  • Structure-Based Optimization of 3-Phenyl-<i>N</i>-(2-(3-phenylureido)ethyl)thiophene-2-sulfonamide Derivatives as Selective Mcl-1 Inhibitors
    作者:Yan Li、Wenjie Fan、Qineng Gong、Jie Tian、Mi Zhou、Qing Li、Laura B. Uwituze、Zhichao Zhang、Ran Hong、Renxiao Wang
    DOI:10.1021/acs.jmedchem.1c00690
    日期:2021.7.22
    Selective Mcl-1 inhibitors may overcome the drug resistance caused by current anti-apoptotic Bcl-2 protein inhibitors in tumors with Mcl-1 overexpression. Based on previously discovered compounds with a 3-phenylthiophene-2-sulfonamide core moiety, in this work, we have obtained new compounds with improved binding affinity and/or selectivity under the guidance of structure-based design. The most potent
    选择性 Mcl-1 抑制剂可能克服当前抗凋亡 Bcl-2 蛋白抑制剂在 Mcl-1 过表达肿瘤中引起的耐药性。基于先前发现的具有 3-苯基噻吩-2-磺酰胺核心部分的化合物,在这项工作中,我们在基于结构的设计指导下获得了具有更高结合亲和力和/或选择性的新化合物。最有效的化合物对 Mcl-1 实现了亚微摩尔的结合亲和力 ( K i ∼ 0.4 μM) 和对几种肿瘤细胞的良好细胞毒性 (IC 50 < 10 μM)。15 N-异核单量子相干核磁共振谱表明这些化合物与 Mcl-1 上的 BH3 结合沟结合。多项细胞分析表明FWJ-D4以及其前体FWJ-D5有效诱导 caspase 依赖性细胞凋亡,并且它们在 Mcl-1 上的靶标参与通过共免疫沉淀实验得到证实。在 RS4;11 异种移植小鼠模型上,每 2 天用 50 毫克/千克的FWJ-D5治疗22 天,导致肿瘤体积减少 75%,而没有体重减轻。
  • 苯并杂环衍生物、其制备方法及其在医药上的 应用
    申请人:江苏恒瑞医药股份有限公司
    公开号:CN107619384B
    公开(公告)日:2020-07-28
    本发明涉及苯并杂环衍生物、其制备方法及其在医药上的应用。特别地,本发明涉及一类如通式(I)所示的化合物,该类化合物具有抗肿瘤的用途,抑制血管生成的作用以及作为HIF‑1α抑制剂在医学上的应用。其中通式(I)中的各取代基与说明书中的定义相同。
  • Sulfonamide derivatives of benzylamine block cholesterol biosynthesis in HepG 2 cells: A new type of potent squalene epoxidase inhibitors
    作者:J.-P. Gotteland、C. Loubat、B. Planty、D. Junquéro、A. Delhon、S. Halazy
    DOI:10.1016/s0960-894x(98)00213-3
    日期:1998.6
    Sulfonamide derivatives of ene-yne benzylamine 1 have been prepared and identified as a new class of potent SE inhibitors having demonstrated activity in HepG2 cells as cholesterol biosynthesis inhibitors.
    制备了烯-炔苄胺1的磺酰胺衍生物,并将其鉴定为一类新型的强效SE抑制剂,已在HepG2细胞中证明了其作为胆固醇生物合成抑制剂的活性。
查看更多

同类化合物

试剂2,5-Dibromo-3,4-dihexylthiophene 苯-1,2,4-三羧酸-丙烷-1,2,3-三醇(1:1) 碘吡咯 癸氯-二茂铁 溴代二茂铁 溴-(3-溴-2-噻嗯基)镁 派瑞林D 派瑞林 F 二聚体 氯代二茂铁 曲洛酯 异噻唑,3-氯-5-甲基- 地茂酮 四碘噻吩 四溴噻吩 四溴吡咯 四溴-N-甲基吡咯 四氯噻吩 四氟噻吩 噻菌腈 噻美尼定. 噻吩,3-溴-4-(1-辛炔基)- 噻吩,2,5-二氯-3,4-二(氯甲基)- 喷贝特 咪唑烷,2-(4-溴-5-甲基-2-呋喃基)-1,3-二甲基- 叔丁基2-溴-4,6-二氢-5H-吡咯并[3,4-D]噻唑-5-羧酸酯 叔-丁基2-溴-5,6-二氢咪唑并[1,2-A]吡嗪-7(8H)-甲酸基酯 八氟联苯烯 八氟二苯并硒吩 二苯基氯化碘盐 二联苯碘硫酸盐 二氯对二甲苯二聚体 二氯[2-甲基-3(2H)-异噻唑酮-O]的钙合物 二氯-1,2-二硫环戊烯酮 二-(3-溴-1,2,4-噻二唑-5-基)-二硫醚 二(2-噻吩基)碘鎓 [四丁基铵][Δ-三(四氯-1,2-苯二醇酸根)磷酸盐(V)] [3-(4-氯-3,5-二甲基-1H-吡唑-1-基)丙基]胺 [3-(4-氯-1H-吡唑-1-基)-2-甲基丙基]胺 [2-(4-溴-吡唑-1-基)-乙基]-二甲胺 [1-(4-溴-3-甲基-1,2-噻唑-5-基)乙亚基氨基]硫脲 [1-(4-溴-1,2-噻唑-3-基)乙亚基氨基]硫脲 [1,1'-联苯]-2,2'-二基碘鎓 [(4-碘-1,2-噻唑-5-基)亚甲基氨基]硫脲 [(4-氯-1,2-噻唑-5-基)亚甲基氨基]硫脲 N-苄基-2-氯吡咯 N-Boc-2-氨基-3-溴噻吩 N-(2-氯-4-甲基-3-噻吩)-4,5-二氢-1H-咪唑-2-胺盐酸盐 N-(2,5-二溴-1H-吡咯-1-基)-氨基甲酸叔丁酯 N,N-二甲基-5-碘-1H-吡唑-1-磺酰胺 N,N-二甲基-2-(3,4,5-三溴吡唑-1-基)丙酰胺